

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT**RECEIVED**

OCT 05 2001

OCT 01 2001

TECH CENTER 1600/2900

ATTORNEY DOCKET NO.
PU3491USWSERIAL NO.
097700,409APPLICANT
LENHARD et alFILING DATE
December 00GROUP
2878

U.S. PATENT DOCUMENTS

Examiner Initials	TRADEMARK OFFICE	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
✓		1. 4,310,003	01/12/1982	Schlager	128	736	
		2. 4,379,461	04/12/1983	Nilsson et al.	128	736	
		3. 4,416,552	11/22/1983	Hessemer, Jr. et al.	374	117	
		4. 4,428,382	01/31/1984	Walsall et al.	128	736	
		5. 4,445,516	05/01/1984	Wollnik et al.	128	736	
		6. 4,501,503	02/26/1985	Buirley et al.	374	162	
		7. 4,602,642	07/29/1986	O'Hara et al.	128	664	
		8. 4,627,442	12/09/1986	Land	128	736	
		9. 4,685,463	08/11/1987	Williams	128	632	
		10. 4,797,840	01/10/1989	Fraden	364	557	
		11. 4,809,707	03/07/1989	Kraft et al.	128	736	
		12. 4,819,657	04/11/1989	Kraft et al.	128	736	
		13. 4,849,885	07/18/1989	Stillwagon et al.	364	413.1	
		14. 4,859,360	08/22/1989	Suzuki et al.	252	299.7	
		15. 4,900,162	02/13/1990	Beckman et al.	374	132	
		16. 4,920,973	05/01/1990	Tanaka et al.	128	736	
		17. 4,947,850	08/14/1990	Vanderkooi et al.	128	654	
		18. 4,955,728	09/11/1990	Hebrank	374	124	
		19. 4,995,398	02/26/1991	Turnidge	128	668	
		20. 4,998,826	03/12/1991	Wood et al.	374	129	
		21. 5,017,019	05/21/1991	Pompei	374	133	
		22. 5,073,503	12/17/1991	Mee	436	147	
		23. 5,077,476	12/31/1991	Rosenthal	250	341	
		24. 5,079,698	01/07/1992	Grenier et al.	364	413.13	
		25. 5,086,229	02/04/1992	Rosenthal et al.	250	341	
		26. 5,115,815	05/26/1992	Hansen	128	664	
		27. 5,200,023	04/06/1993	Gifford et al.	156	626	
		28. 5,215,095	06/01/1993	Macvicar et al.	128	665	
		29. 5,285,396	02/08/1994	Aoyama	364	557	
		30. 5,301,681	04/12/1994	DeBan et al.	128	736	
		31. 5,340,745	08/23/1994	Wojciechowski et al.	436	34	
		32. 5,356,217	10/18/1994	Sheffield	374	45	
		33. 5,370,121	12/06/1994	Reichenberger et al.	128	660.02	
		34. 5,375,603	12/27/1994	Feiler	128	664	
		35. 5,377,126	12/27/1994	Flik et al.	364	557	
		36. 5,386,831	02/07/1995	Gluck	128	664	
		37. 5,420,042	05/30/1995	Schäfer et al.	436	517	
		38. 5,458,418	10/17/1995	Jones et al.	374	45	
		39. 5,465,718	11/14/1995	Hochman et al.	128	653.1	
		40. 5,539,673	07/23/1996	Charm et al.	364	557	
		41. 5,551,780	09/03/1996	Wintrich et al.	374	45	
		42. 5,578,827	11/26/1996	Wolf et al.	250	339,04	
		43. 5,595,444	01/21/1997	Tong et al.	374	45	
		44. 5,653,537	08/05/1997	Ignatowicz et al.	374	131	
		45. 5,653,539	08/05/1997	Rosengaus	374	159	

Continue on page 2

EXAMINER

DATE CONSIDERED

7/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT OCT 05 2001 TECH CENTER 1600/2900				ATTORNEY DOCKET NO. PU3491USW	SERIAL NO. 09/700,409
				APPLICANT LENHARD et al.	
				FILING DATE December 11, 2000	GROUP 2878

U.S. PATENT DOCUMENTS (Continued)

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	46. 5,666,962	09/16/1997	Lamey	128	736	
	47. 5,692,510	12/02/1997	Gordon et al.	128	654	
	48. 5,696,703	12/09/1997	Barber	364	557	
	49. 5,699,797	12/23/1997	Godik	128	653.1	
	50. 5,740,809	04/21/1998	Baratta	128	664	
	51. 5,771,261	06/23/1998	Anbar	374	45	
	52. 5,792,667	08/11/1998	Florin et al.	436	147	
	53. 5,795,305	08/18/1998	Cho et al.	600	549	

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	54. WO 99/21957	05/06/1999	WIPO	C12M	1/34	X

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

55. Ahmad-Junan et al., "Synthetic studies on electron transport inhibitors related to natural products", *Mitochondrial Electron Transport Inhibitors* 22:237-241 (1994).
56. Astrup et al., "Enhanced thermogenic responsiveness during chronic ephedrine treatment in man", *The American Journal of Clinical Nutrition* 42:83-94 (July 1985).
57. Blaak et al., "Adrenoceptor subtypes mediating catecholamine-induced thermogenesis in man", *International Journal of Obesity* 17:(Suppl. 3) S78-S81 (1993).
58. Böttcher et al., "A new microcatheter enables microcalorimetric assessment of thermogenesis after stimulation in cell cultures", *J. Biochem. Biophys. Methods* 32:191-194 (1996).
59. Carr et al., "Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study", *The Lancet* 353:2093-2099 (June 1999).
60. Champigny et al., "Evidence from in vitro differentiating cells that adrenoceptor agonists can increase uncoupling protein mRNA level in adipocytes of adult humans: an RT-PCR study", *Journal of Lipid Research* 37:1907-1914 (1996).
61. Enerbäck et al., "Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese", *Nature* 387:90-94 (May 1997).
62. Ferrara et al., "The Biology of Vascular Endothelial Growth Factor", *Endocrine Reviews* 18:14-25 (1997).
63. Fleury et al., "Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia", *Nature Genetics* 15:269-272 (March 1997).
64. Henke et al., "N-(2-Benzoylphenyl)-L-tyrosine PPAR γ Agonists. I. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents", *J. Med. Chem.* 41:25 5020-5036 (1998).
65. Himms-Hagen, "Minireview: Role of Brown Adipose Tissue Thermogenesis in Control of Thermoregulatory Feeding in Rats: A New Hypothesis That Links Thermostatic and Glucostatic Hypotheses for Control of Food Intake (43847A)", *Proc. Soc. Exp. Bio. Med.* 208:159-169 (1995).
66. Hoveyda, "Catalyst discovery through combinatorial chemistry", *Chemistry & Biology* 5:R187-R191 (August 1998).
67. Kenakin et al., " β -Adrenoceptor Assays", *Current Protocols in Pharmacology* 4.6.1-4.6.36 (1998).
68. Koenigbauer, "Pharmaceutical Applications of Microcalorimetry", *Pharmaceutical Research* 11:6 777-783 (1994).
69. Lafontan et al., "Fat cell adrenergic receptors and the control of white and brown fat cell function", *Journal of Lipid Research* 34:1057-1091 (1993).

Continue on page 3

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>7/15/2</i>
-----------------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

OCT 05 2001

OCT 01 2001

TECH CENTER 1600/2900

ATTORNEY DOCKET NO.

PU3491USW

SERIAL NO.

09/700,409

APPLICANT

LENHARD et al.

FILING DATE

December 11, 2000

GROUP

2878

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) (Continued)

- PATENT & TRADEMARK OFFICE
OCT 1 2001
SCA1
70. Lehmann et al., "An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPAR γ)", *The Journal of Biological Chemistry* 270:22 12953-12956 (June 1995).
71. Lenhard et al., "Effects of Troglitazone and Metformin on Glucose and Lipid Metabolism", *Biochemical Pharmacology* 54:801-808 (1997).
72. Moates et al., "Infrared Thermographic Screening of Combinatorial Libraries of Heterogeneous Catalysts", *Ind. Eng. Chem. Res.* 35:12 4801-4803 (1996).
73. Nedergaard et al., "[3 H]GDP binding and thermogenin amount in brown adipose tissue mitochondria from cold-exposed rats", *Am. J. Physiol.* 248(Cell Physiol. 17):C365-C371 (1985).
74. Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells", *Cell Tissue Res.* 290:79-87 (1997).
75. Reers et al., "J-Aggregate Formation of a Carbocyanine as a Quantitative Fluorescent Indicator of Membrane Potential", *Biochemistry* 30:18 4480-4486 (1991).
76. Rehnmark et al., "Brown Adipocytes Differentiated *in Vitro* Can Express the Gene for the Uncoupling Protein Thermogenin: Effects of Hypothyroidism and Norepinephrine", *Experimental Cell Research* 182:75-83 (1989).
77. Rehnmark et al., " α - and β -Andrenergic Induction of the Expression of the Uncoupling Protein Thermogenin in Brown Adipocytes Differentiated in Culture", *The Journal of Biological Chemistry* 265:27 16464-16471 (September 1990).
78. Ricquier et al., "Molecular studies of the uncoupling protein", *FASEB J.* 5:2237-2242 (1991).
79. Scarpace, "Thermoregulation with Age: Role of Beta-Adrenergic Signal Transduction", *Annals New York Academy of Sciences* 813:111-116 (1997).
80. Shimabukuro et al., "Induction of Uncoupling Protein-2 mRNA by Troglitazone in the Pancreatic Islets of Zucker Diabetic Fatty Rats", *Biochemical and Biophysical Research Communications* 237:359-361 (1997).
81. Silva, "Full Expression of Uncoupling Protein Gene Requires the Concurrence of Norepinephrine and Triiodothyronine", *Molecular Endocrinology* 2:8 706-713 (1988).
82. Stock, "Sibutramine: a review of the pharmacology of a novel anti-obesity agent", *International Journal of Obesity* 21:Suppl. 1 S25-S29 (1997).
83. Surwit et al., "Differential Effects of Fat and Sucrose on the Development of Obesity and Diabetes in C57BL/6J and A/J Mice", *Metabolism* 44:5 645-651 (May 1995).
84. Tai et al., "Activation of the Nuclear Receptor Peroxisome Proliferator-activated Receptor γ Promotes Brown Adipocyte Differentiation", *The Journal of Biological Chemistry* 271:47 29909-29914 (November 1996).
85. Terada, "The Interaction of Highly Active Uncouplers With Mitochondria", *Biochimica et Biophysica Acta* 639:225-242 (1981).

Continue on page _____

EXAMINER

DATE CONSIDERED
7/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.